Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18266083 | Sulfoximine Pesticides | Non-Final OA | BASF SE |
| 17745621 | DUAL ANDROGEN RECEPTOR/AKR1C3 INHIBITORS | Final Rejection | Ohio State Innovation Foundation |
| 17823028 | METHODS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17702578 | METHODS FOR REDUCING REWARDING EFFECTS OF MORPHINE WITHOUT AFFECTING ITS ANALGESIC EFFECTS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17599207 | BRYOSTATIN COMPOUNDS FOR ENHANCEMENT OF IMMUNOTHERAPY | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17618838 | DIBENZYLAMINES AS AMINO ACID TRANSPORT INHIBITORS | Final Rejection | VANDERBILT UNIVERSITY |
| 17596466 | HDAC3 CATALYTIC INHIBITOR DEVELOPMENT AND USES THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17290987 | NOVEL SELECTIVE KAPPA OPIOID RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO | Final Rejection | TEXAS TECH UNIVERSITY SYSTEM |
| 17625976 | TARGETING PTPN22 IN CANCER THERAPY | Non-Final OA | The Johns Hopkins University |
| 18258746 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17462872 | ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER | Final Rejection | Eli Lilly and Company |
| 18281480 | COMPOSITION FOR TREATMENT OF ANTICANCER AGENT-RESISTANT CANCER | Non-Final OA | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY |
| 18383708 | PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARy) LIGANDS AND METHODS OF USE AS TREATMENTS FOR INSULIN RESISTANCE, OBESITY, FATTY LIVER DISEASE, AND TYPE 2 DIABETES | Non-Final OA | The Board of Regents of the University of Oklahoma |
| 18546850 | METHOD FOR MANUFACTURING AZOLE DERIVATIVE | Final Rejection | Kureha Corporation |
| 18255655 | METHODS OF TREATING AND PREVENTING KIDNEY DISEASE | Non-Final OA | Washington University |
| 18256650 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | Final Rejection | BAYER AKTIENGESELLSCHAFT |
| 18453163 | CDK2 INHIBITORS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 18036853 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Non-Final OA | BIOGEN MA INC. |
| 18344560 | CD73 COMPOUNDS | Final Rejection | Gilead Sciences, Inc. |
| 18256982 | Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 17924610 | CIRCULATING B CELL SUBPOPULATIONS IN INDOLENT B CELL LYMPHOMA | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18275178 | PYRIMIDOPYRAN COMPOUND | Non-Final OA | D3 Bio (Wuxi) Co., Ltd. |
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | Non-Final OA | BeiGene Switzerland GmbH |
| 17770704 | USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND FOR PREVENTION, ALLEVIATION, OR TREATMENT OF DEVELOPMENTAL DISABILITY | Final Rejection | SK BIOPHARMACEUTICALS CO., LTD. |
| 18289970 | INHIBITORS OF THE MENIN-MLL INTERACTION | Non-Final OA | Vitae Pharmaceuticals, LLC |
| 17996427 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | Non-Final OA | Augusta University Research Institute, Inc. |
| 18493435 | ANTIOXIDANT COMPOSITIONS AND METHODS OF USE | Non-Final OA | Sanare Pharmaceuticals |
| 18487811 | ACETAL, KETAL, AND HEMIAMINAL ANALOGS OF PSILOCIN, PROCESSES FOR THE PREPARATION THEREOF, AND METHODS OF USE | Non-Final OA | Invyxis, Inc. |
| 18286970 | PYRIDOSTIGMINE FOR USE IN THE TREATMENT OF COVID-19 | Non-Final OA | INSTITUTO NACIONAL DE CIENCIAS MEDICAS Y NUTRICION SALVADOR ZUBIRAN |
| 18286961 | KRAS G12C INHIBITORS | Non-Final OA | Mirati Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy